Straumann introduces new implant material in Europe

BASEL, Switzerland/LEIPZIG, Germany: Straumann's dental implant alloy Roxolid is now available to dentists in Europe. Following the recent launch in North America, the material was introduced at the 18th Annual Meeting of the European Association for Osseointegration (EAO) in Monaco. Roxolid combines high tensile and fatigue strengths with excellent osseointegration, according to latest clinical research. It is designed to increase reliability and confidence especially with small diameter implants.

Involving 60 centers and more than 300 patients, Roxolid has been undergoing one of the largest clinical research programmes ever undertaken by a dental implant company in recent years. To date, two more large multicenter clinical trials are in progress.

Company officials announced today that the clinical programme has been extended to include studies looking specifically at the need for bone augmentation and at the performance of Roxolid in the front of the mouth and in narrow spaces. In addition, preclinical testing has been broadened to investigate healing characteristics and to draw direct comparisons with other titanium alloys.

Roxolid is available with Ø3.3mm Bone and Soft Tissue Level implants.